IGC Pharma Receives Canadian Patent for Alzheimer's Agitation Drug Candidate IGC-AD1

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment

IGC Pharma Announces Completion Of 168-Patient Enrollment In Phase 2 Trial Of IGC-AD1 For Alzheimer's Agitation; Topline Data Expected Q4 2026

'Federal Court Rejects Marijuana Opponents’ Request To Block Trump’s Rescheduling Move' - Marijuana Moment

https://www.marijuanamoment.net/federal-court-rejects-marijuana-opponents-request-to-block-trumps-rescheduling-move/

President And Founder Of Seabreeze Capital Partners LP Dougie Kass Posts On X "We have moved to super size $MSOS and individual cannabis stocks in the belief that a favorable rescheduling announcement will come shortly."

https://x.com/DougKass/status/2093394146182480247

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6

Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.